Abstract
Adjuvant immunotherapy is currently moving into earlier stages of melanoma. CPG7909, a Toll-like receptor-9 (TLR9) agonist, injected at the primary tumour excision site in patients with clinical stage I/II melanoma, was found to boost loco-regional and systemic anti-melanoma immunity. In an exploratory analysis this was accompanied by a significant decrease in tumour-positive sentinel lymph node (SLN) rates and improved recurrence-free survival (RFS). To confirm these results we performed a randomized, placebo-controlled and double-blind phase II study of TLR9 agonist IMO-2125 in stage II pT3-4/cN0 melanoma.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
